Teclistamab Clinical Trials (2026): 50 Studies for Multiple Myeloma & Refractory Multiple Myeloma
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
50 Teclistamab clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 18 indications (including Multiple Myeloma & Refractory Multiple Myeloma) and 10,627 total planned enrollment. 7 Phase 3 Teclistamab trials and 22 Phase 2, 3 Phase 4 are listed. 32 Teclistamab clinical trials are actively recruiting at 183 U.S. sites across 38 states. Most recent activity: NCT06855121 (Dec 2037).
Where to Participate: All Teclistamab Trial Sites in the U.S. (183 sites across 38 states)
Every actively recruiting Teclistamabtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| AZ | Banner MD Anderson Cancer Center | Gilbert85234 | NCT05552222 | Map |
| AZ | Banner University Medical Center Tucson, University of Arizona | Phoenix85004 | NCT05243797 | Map |
| AZ | Mayo Clinic Hospital in Arizona | Phoenix85054 | NCT06465316 | Map |
| AZ | Arizona Oncology Associates | Tucson85711 | NCT05972135 | Map |
| AZ | University of Arizona Cancer Center | Tucson85719 | NCT05552222 | Map |
| AR | Highlands Oncology Group | Springdale72762 | NCT07518186 | Map |
| CA | UCSF Fresno | Clovis93611 | NCT05552222 | Map |
| CA | City of Hope Duarte | Duarte91010 | NCT05552222 | Map |
| CA | City of Hope Orange County Lennar Foundation Cancer Center | Irvine92618 | NCT05552222 | Map |
| CA | Cancer and Blood Specialty Clinic | Los Alamitos90720 | NCT05552222 | Map |
| CA | USC Norris Comprehensive Cancer Center | Los Angeles90033 | NCT07258511 | Map |
| CA | Valkyrie Clinical Trials | Los Angeles90067 | NCT05552222 | Map |
| CA | University of California-Davis Cancer Center | Sacramento95817 | NCT05243797 | Map |
| CA | University of California, San Diego (UCSD) Medical Center | San Diego92093 | NCT05243797 | Map |
| CO | University of Colorado Hospital | Aurora80045 | NCT05243797 | Map |
| CO | Colorado Blood Cancer Institute | Denver80218 | NCT05243797 | Map |
| CO | Colorado Blood Cancer Institute | Denver80218 | NCT05469893 | Map |
| CO | Colorado Blood Cancer Institute | Denver80218 | NCT05972135 | Map |
| CO | Colorado Blood Cancer Institute | Denver80218 | NCT07258511 | Map |
| CO | Rocky Mountain Cancer Center | Denver80218 | NCT05972135 | Map |
| CT | Smilow Cancer Hospital-Derby Care Center | Derby06418 | NCT06465316 | Map |
| CT | University of Connecticut | Farmington06030 | NCT05552222 | Map |
| CT | University of Connecticut Health Center | Farmington06030 | NCT07258511 | Map |
| CT | Smilow Cancer Hospital Care Center - Guilford | Guilford06437 | NCT06465316 | Map |
| CT | Yale Cancer Center | New Haven06510 | NCT07258511 | Map |
| CT | Yale New Haven Hospital | New Haven06519 | NCT05243797 | Map |
| CT | Yale New Haven Hospital | New Haven06510 | NCT05552222 | Map |
| CT | Yale University | New Haven06520 | NCT06465316 | Map |
| CT | Yale University | New Haven06519 | NCT06993675 | Map |
| CT | Yale-New Haven Hospital North Haven Medical Center | North Haven06473 | NCT06465316 | Map |
| DE | Christiana Care | Newark19718 | NCT05243797 | Map |
| DE | ChristianaCare Helen F Graham Cancer Center and Research Institute | Newark19713 | NCT05552222 | Map |
| DE | Medical Oncology Hematology Consultants | Newark19713 | NCT05972135 | Map |
| DE | Medical Oncology Hematology Consultants, PA | Newark19713 | NCT06208150 | Map |
| DC | Sibley Memorial Hospital | Washington D.C.20016 | NCT05243797 | Map |
| FL | Florida Cancer Specialists & Research Institute | Fort Myers33901 | NCT07258511 | Map |
| FL | Memorial Healthcare System | Hollywood33021 | NCT05552222 | Map |
| FL | Mayo Clinic in Florida | Jacksonville32224-9980 | NCT06465316 | Map |
| FL | University of Miami | Miami33136 | NCT06100237 | Map |
| FL | AdventHealth Medical Group Blood & Marrow Transplant at Orlando | Orlando32804 | NCT05552222 | Map |
| FL | AdventHealth/Blood & Marrow Transplant Center, Florida Hospital Medical Group | Orlando32804 | NCT05243797 | Map |
| FL | Moffit Cancer center | Tampa33612 | NCT07258511 | Map |
| FL | Moffitt at Memorial Healthcare System | Tampa33612 | NCT05243797 | Map |
| FL | Cleveland Clinic Florida | Weston33331 | NCT05552222 | Map |
| GA | Emory University | Atlanta30322 | NCT07258511 | Map |
| GA | Emory University Hospital | Atlanta30322 | NCT05243797 | Map |
| GA | Emory Winship Cancer Institute | Atlanta30322 | NCT04068597 | Map |
| GA | City of Hope Cancer Center | Newnan30265 | NCT05552222 | Map |
| GA | City of Hope Cancer Center | Newnan30265 | NCT06208150 | Map |
| IL | University Of Illinois Medical Center | Chicago60612 | NCT05552222 | Map |
| IL | University of Illinois Medical Center at Chicago | Chicago60612 | NCT05243797 | Map |
| IL | Loyola University Medical Center | Maywood60153 | NCT05552222 | Map |
| IN | Community Health Network | Indianapolis46227 | NCT04068597 | Map |
| IA | University of Iowa Hospital and Clinics | Iowa City52242 | NCT07258511 | Map |
| IA | Mission Cancer Blood | Waukee50263 | NCT07258511 | Map |
| IA | University of Iowa Health Care | Waukee50263 | NCT05552222 | Map |
| KS | University of Kansas Cancer Center | Kansas City66160 | NCT06465316 | Map |
| KS | University of Kansas Cancer Center-Overland Park | Overland Park66210 | NCT06465316 | Map |
| KS | University of Kansas Hospital-Westwood Cancer Center | Westwood66205 | NCT06465316 | Map |
| KY | Norton Cancer Institute | Louisville40207 | NCT05552222 | Map |
| KY | Norton Cancer Institute | Louisville40207 | NCT07258511 | Map |
| LA | Our Lady of the Lake Hospital | Baton Rouge70808 | NCT06208150 | Map |
| LA | LSUHSC Shreveport Feist-Weiller Cancer Center | Shreveport71103 | NCT05552222 | Map |
| MD | Greenebaum Cancer Center UM of MD | Baltimore21201 | NCT05243797 | Map |
| MD | John Hopkins | Baltimore21218 | NCT05243797 | Map |
| MD | Johns Hopkins University School of Medicine JHUSOM | Baltimore21231 | NCT05552222 | Map |
| MD | University of Maryland School of Medicine | Baltimore21201 | NCT06208150 | Map |
| MD | Center for Cancer and Blood Disorders | Bethesda20817 | NCT05552222 | Map |
| MD | The Center for Cancer and Blood Disorders (CCBD) | Bethesda20817 | NCT04068597 | Map |
| MD | Maryland Oncology Hematology | Columbia21044 | NCT05972135 | Map |
| MA | Beth Israel Deaconess Medical Center | Boston02215 | NCT05243797 | Map |
| MA | Dana Farber Cancer Institute | Boston02115 | NCT05469893 | Map |
| MA | Tufts Medical Center | Boston02111 | NCT05243797 | Map |
| MI | University of Michigan | Ann Arbor48109 | NCT05552222 | Map |
| MI | Henry Ford Cancer - Detroit Brigitte Harris Cancer Pavilion | Detroit48202 | NCT05552222 | Map |
| MI | Henry Ford Cancer Institute | Detroit48202 | NCT06208150 | Map |
| MI | Cancer And Hematology Centers of Western Michigan PC | Grand Rapids49503 | NCT05552222 | Map |
| MI | Henry Ford Providence Novi Hospital | Novi48374 | NCT05552222 | Map |
| MI | Henry Ford Providence Southfield CK Potluri Cancer Center | Southfield48075 | NCT05552222 | Map |
| MN | Minnesota Oncology Hematology | Minneapolis55404 | NCT05972135 | Map |
| MN | Mayo Clinic in Rochester | Rochester55905 | NCT06465316 | Map |
| MO | MidAmerica Cancer Care | Kansas City64132 | NCT05552222 | Map |
| NE | Nebraska Cancer Specialists | Omaha68130 | NCT05552222 | Map |
| NE | Nebraska Cancer Specialists | Omaha68130 | NCT04068597 | Map |
| NE | Nebraska Cancer Specialists | Omaha68130 | NCT07518186 | Map |
| NE | University of Nebraska Medical Center | Omaha68198 | NCT05552222 | Map |
| NE | University of Nebraska Medical Center | Omaha68198-6846 | NCT04068597 | Map |
| NH | Dartmouth Hitchcock Medical Center | Lebanon03756 | NCT05552222 | Map |
| NJ | Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) | Basking Ridge07920 | NCT07105059 | Map |
| NJ | Astera Cancer Care | East Brunswick08816 | NCT05552222 | Map |
| NJ | Memorial Sloan Kettering Monmouth (Limited Protocol Activities) | Middletown07748 | NCT07105059 | Map |
| NJ | Memorial Sloan Kettering Bergen (Limited Protocol Activities) | Montvale07645 | NCT07105059 | Map |
| NM | Christus St. Vincent Regional Cancer Center | Santa Fe87505 | NCT05552222 | Map |
| NY | Mount Sinai Brooklyn | Brooklyn11234 | NCT07258511 | Map |
| NY | Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities) | Commack11725 | NCT07105059 | Map |
| NY | Hematology-Oncology Associates of CNY | East Syracuse13057 | NCT05552222 | Map |
| NY | Memorial Sloan Kettering Westchester (Limited Protocol Activities) | Harrison10604 | NCT07105059 | Map |
| NY | Northwell Health Cancer Institute | Lake Success11042 | NCT05552222 | Map |
| NY | NYU Langone Hospital Long Island | Mineola11500 | NCT05552222 | Map |
| NY | NYU Winthrop | Mineola11501 | NCT07258511 | Map |
| NY | Columbia University Irving Medical Center | New York10032 | NCT07110844 | Map |
| NY | Icahn School of Medicine at Mount Sinai | New York10029 | NCT07258511 | Map |
| NY | Laura and Isaac Perlmutter Cancer Center NYU ACC | New York10016 | NCT07258511 | Map |
| NY | Memorial Sloan Kettering Cancer Center | New York10065 | NCT05552222 | Map |
| NY | Memorial Sloan Kettering Cancer Center | New York10065 | NCT07258511 | Map |
| NY | Memorial Sloan Kettering Cancer Center (All Protocol Activities) | New York10065 | NCT07105059 | Map |
| NY | Mount Sinai Chelsea | New York10011 | NCT07258511 | Map |
| NY | Mount Sinai Medical Center - 2 | New York10029 | NCT05243797 | Map |
| NY | Perlmutter Cancer Center at NYU Langone Health | New York10016 | NCT05552222 | Map |
| NY | Weill Cornell Medical College | New York10065 | NCT05552222 | Map |
| NY | Weill Cornell Medical College | New York10065 | NCT06208150 | Map |
| NY | SUNY Upstate Medical University | Syracuse13210 | NCT06208150 | Map |
| NY | Montefiore Medical Cente | The Bronx10467 | NCT05243797 | Map |
| NY | Memorial Sloan Kettering Nassau (Limited Protocol Activities) | Uniondale11553 | NCT07105059 | Map |
| NC | Levine Cancer Institute | Charlotte28204 | NCT05243797 | Map |
| NC | Levine Cancer Institute | Charlotte28204 | NCT05552222 | Map |
| NC | Novant Health | Charlotte28204 | NCT05552222 | Map |
| NC | Duke University | Durham27710 | NCT05243797 | Map |
| NC | Durham VAMC | Durham27705 | NCT05552222 | Map |
| NC | Durham VAMC | Durham27705 | NCT07258511 | Map |
| NC | Virginia Oncology Associates | Elizabeth City27909 | NCT05972135 | Map |
| NC | Novant Health Zimmer Cancer Institute | Wilmington28401 | NCT05552222 | Map |
| NC | Atrium Health Wake Forest Baptist Comprehensive Cancer Center | Winston-Salem27157 | NCT05552222 | Map |
| NC | Novant Health Forsyth Medical Center | Winston-Salem27103 | NCT05552222 | Map |
| OH | Oncology Hematology Care | Cincinnati45236 | NCT05552222 | Map |
| OH | Oncology Hematology Care | Cincinnati45242 | NCT05972135 | Map |
| OH | The Christ Hospital Cancer Center | Cincinnati45219 | NCT05552222 | Map |
| OH | University of Cincinnati | Cincinnati45221 | NCT05243797 | Map |
| OH | University of Cincinnati | Cincinnati45267 | NCT05552222 | Map |
| OH | Cleveland Clinic Main Campus | Cleveland44195 | NCT05552222 | Map |
| OH | Seidman Cancer Center-University Hospitals Cleveland Medical Center | Cleveland44106 | NCT05243797 | Map |
| OH | University Hospitals Cleveland Medical Center | Cleveland44106 | NCT05552222 | Map |
| OH | Ohio Health Research Institute | Columbus43214 | NCT05243797 | Map |
| OH | Ohio State Medical Center, James Cancer Center | Columbus43210 | NCT05243797 | Map |
| OH | Ohio State University Comprehensive Cancer Center | Columbus43210 | NCT06465316 | Map |
| OH | OhioHealth | Columbus43214 | NCT05552222 | Map |
| OH | The Ohio State University- James Cancer Hospital | Columbus43210 | NCT05552222 | Map |
| OK | University of Oklahoma Health Sciences Center | Oklahoma City73104 | NCT06465316 | Map |
| OR | Oncology Associates of Oregon | Eugene97401 | NCT05972135 | Map |
| OR | Oregon Health & Science University | Portland97239 | NCT05469893 | Map |
| OR | Oregon Health And Science University | Portland97239 | NCT07258511 | Map |
| PA | Lehigh Valley Health Network | Allentown18103 | NCT05243797 | Map |
| PA | Penn State Milton S Hershey Medical Ctr | Hershey17033 | NCT05552222 | Map |
| PA | Abramson Cancer Center University of Pennsylvania Medical Center | Philadelphia19104 | NCT05243797 | Map |
| PA | Fox Chase Cancer Center | Philadelphia19111 | NCT05243797 | Map |
| PA | Penn Medicine - Abramson Cancer Center Perelman | Philadelphia19104 | NCT04068597 | Map |
| PA | Thomas Jefferson University Hospital | Philadelphia19107 | NCT07258511 | Map |
| PA | Allegheny Health Network | Pittsburgh15224 | NCT05552222 | Map |
| RI | Rhode Island Hospital | Providence02903 | NCT05552222 | Map |
| SC | Medical University of South Carolina | Charleston29425-8900 | NCT06208150 | Map |
| SC | Medical University of South Carolina (MUSC) | Charleston29425 | NCT05243797 | Map |
| SC | MUSC-Hollings Cancer Center | Charleston29425 | NCT05552222 | Map |
| SC | Gibbs Cancer Center | Spartanburg29303 | NCT05243797 | Map |
| TN | Henry-Joyce Cancer Clinic | Nashville37232 | NCT05552222 | Map |
| TN | SCRI Oncology Partners | Nashville37203 | NCT07258511 | Map |
| TN | TriStar Bone Marrow Transplant | Nashville37203 | NCT05972135 | Map |
| TN | Vanderbilt- Ingram Cancer Center | Nashville37232 | NCT05972135 | Map |
| TN | Vanderbilt-Ingram Cancer Center (VICC) | Nashville37232 | NCT05243797 | Map |
| TX | St. David's South Austin Medical Center | Austin78704 | NCT07258511 | Map |
| TX | Texas Oncology | Austin78705 | NCT05972135 | Map |
| TX | Baylor University Medical Center | Dallas75246 | NCT07258511 | Map |
| TX | University of Texas Southwestern Medical Center | Dallas75235 | NCT05552222 | Map |
| TX | Houston Methodist Hospital | Houston77030 | NCT05243797 | Map |
| TX | Houston Methodist Hospital | Houston77030 | NCT05552222 | Map |
| TX | Joe Arrington Cancer Research Treatment Center | Lubbock79410 | NCT05552222 | Map |
| TX | Texas Oncology - San Antonio | San Antonio78240 | NCT05972135 | Map |
| TX | Texas Oncology - Northeast Texas | Tyler75702 | NCT05972135 | Map |
| UT | Huntsman Cancer Institute | Salt Lake City84112 | NCT05552222 | Map |
| UT | Huntsman Cancer Institute | Salt Lake City84112 | NCT07258511 | Map |
| UT | Utah Cancer Specialists | Salt Lake City84106 | NCT05552222 | Map |
| VA | Virginia Cancer Specialists | Fairfax22031 | NCT05972135 | Map |
| VA | Alexander T. Augusta Military Medical Center | Fort Belvoir22060 | NCT05552222 | Map |
| VA | Virginia Oncology Associates | Norfolk23502 | NCT05243797 | Map |
| VA | Virginia Oncology Associates Brock Cancer Center | Norfolk23502 | NCT05552222 | Map |
| VA | Richmond VA Medical Center | Richmond23249 | NCT05552222 | Map |
| VA | VCU Massey Comprehensive Cancer Center | Richmond23298 | NCT06465316 | Map |
| VA | Virginia Commonwealth University Medical Center | Richmond23298 | NCT05552222 | Map |
| VA | Blue Ridge Cancer Center | Roanoke24014 | NCT05972135 | Map |
| WA | NorthWest Medical Specialties, PLLC | Tacoma98405 | NCT05552222 | Map |
| WI | St Vincent HSHS (Green Bay Oncology) | Green Bay54301 | NCT05243797 | Map |
| WI | Gundersen Health System | La Crosse54601 | NCT06208150 | Map |
| WI | University of Wisconsin Hospital and Clinics | Madison53792 | NCT05243797 | Map |
| WI | Froedtert Memorial Lutheran Hospital | Milwaukee53226 | NCT05243797 | Map |
Teclistamab clinical trials at a glance: phase × recruitment status
| Phase | recruiting | active not recruiting | completed | terminated | withdrawn | not yet recruiting | no longer available | approved for marketing | Total |
|---|---|---|---|---|---|---|---|---|---|
| P1 | 2 | 5 | 1 | 1 | 9 | ||||
| P1/P2 | 1 | 1 | 1 | 1 | 4 | ||||
| P2 | 13 | 5 | 1 | 3 | 22 | ||||
| P3 | 5 | 2 | 7 | ||||||
| P4 | 2 | 1 | 3 | ||||||
| N/A | 3 | 1 | 1 | 5 |
Recruiting Teclistamab clinical trials (32)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT06855121 | NIMMSThe Norwegian Immunotherapy in Multiple Myeloma Study | — | Myeloma Multiple | 400 | Jan 2025 |
| NCT07474961 | BLOOD-doseBLOOD-dose: A Platform Trial Evaluating Dose Optimization in Hematological Diseases. | P4 | Waldenstrom Macroglobulinaemia | 400 | Mar 2027 |
| NCT07107529 | Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab. | P2 | Multiple Myeloma (MM) | 150 | Dec 2025 |
| NCT07110844 | Teclistamab-Daratumumab in AL Amyloidosis | P2 | Amyloid Light-chain Amyloidosis | 25 | Nov 2025 |
| NCT05552222 | MajesTEC-7A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma | P3 | Multiple Myeloma | 1,590 | Oct 2022 |
| NCT07518186 | TRIlogy-5A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma | P3 | Multiple Myeloma | 700 | May 2026 |
| NCT05243797 | MajesTEC-4Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation | P3 | Multiple Myeloma | 1,594 | Sep 2022 |
| NCT07029776 | MMulti-Immune HR; Multi-Target Immunotherapy for High-Risk Multiple Myeloma | P2 | Multiple Myeloma (MM) | 50 | Jul 2026 |
| NCT07258511 | TRIlogy-4A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma | P3 | Multiple Myeloma | 400 | Feb 2026 |
| NCT05572229 | IFM2021-01Study of Teclistamab in Combination in Elderly Patients With Multiple Myeloma | P2 | Multiple Myeloma | 74 | Dec 2023 |
| NCT05469893 | Immuno-PRISM (PRecision Intervention Smoldering Myeloma) | P2 | High-risk Smoldering Multiple Myeloma | 52 | Aug 2022 |
| NCT06100237 | REVIVETeclistamab in Combination With Daratumumab for High-Risk Smoldering Myeloma: A Clinical and Correlative Phase 2 Immuno-Oncology Study (the REVIVE Study) | P2 | Multiple Myeloma | 50 | Dec 2023 |
| NCT06880601 | TALIMTeclistamab Plus Autologous Lymphocyte Infusion (ALI) for the Treatment of R/R Multiple Myeloma | P2 | Multiple Myleoma | 52 | Nov 2025 |
| NCT05695508 | HD10/DSMMXXGMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5 | P2 | Multiple Myeloma | 160 | Dec 2022 |
| NCT06993675 | ROTATEEngaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE) | P2 | Multiple Myeloma | 50 | Aug 2025 |
| NCT06935162 | Teclistamab in Previously Treated AL Amyloidosis | P2 | AL Amyloidosis | 30 | May 2025 |
| NCT06208150 | MonumenTAL-6A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide | P3 | Multiple Myeloma | 795 | Jan 2024 |
| NCT06505369 | TALTECBispecific T-cell Redirectors as Part of First Line Treatment in Transplant Eligible Multiple Myeloma Patients | P2 | Multiple Myeloma | 50 | Jun 2024 |
| NCT06649695 | ALA Phase II Trial of Teclistamab in Participants With Previously Treated Immunoglobulin Light-chain (AL) Amyloidosis | P2 | AL Amyloidosis | 30 | Jul 2025 |
| NCT07105059 | A Study of Teclistamab and Mezigdomide in People With Multiple Myeloma | P1 | Multiple Myeloma | 18 | Aug 2025 |
| NCT06948084 | Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse | P2 | Recurrent Multiple Myeloma | 80 | Aug 2026 |
| NCT07079423 | Teclistamab in Newly Diagnosed Mayo Stage IIIB AL Amyloidosis | P2 | AL Amyloidosis | 35 | Jun 2025 |
| NCT05972135 | Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma | P2 | Multiple Myeloma | 100 | Oct 2023 |
| NCT06477783 | TECTONICStudy on the Clinical Efficacy of Teclistamab | — | Multiple Myeloma | 100 | Dec 2024 |
| NCT07030517 | A Study to Assess Safety of Teclistamab in Indian Participants With Relapsed and Refractory Multiple Myeloma | P4 | Multiple Myeloma | 75 | May 2025 |
| NCT04068597 | Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies | P1/P2 | Haematological Malignancy | 250 | Aug 2019 |
| NCT07332507 | Testing the Effect of Teclistamab on Recurrent Plasmablastic Lymphoma | P1 | Recurrent Plasmablastic Lymphoma | 30 | May 2026 |
| NCT06699394 | Prospective Study of Teclistamab in the Treatment of Systemic AL Amyloidosis | N/A | AL Amyloidosis | 20 | Mar 2025 |
| NCT06465316 | TECVAYLITesting Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma | P1 | Recurrent Multiple Myeloma | 26 | Dec 2024 |
| NCT06758375 | Low Dose Teclistamab in Newly Diagnosed Multiple Myeloma Patients | P2 | Multiple Myeloma, Newly Diagnosed | 10 | Mar 2025 |
| NCT06251076 | Plan Development for Giving Teclistamab in the Outpatient Setting | P4 | Multiple Myeloma | 15 | Nov 2024 |
| NCT07463807 | Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment | P1/P2 | Recurrent Multiple Myeloma | 162 | Jun 2026 |
Teclistamab clinical trials by indication
Multiple Myeloma (23)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05552222 | MajesTEC-7 | P3 | recruiting | A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma |
| NCT07518186 | TRIlogy-5 | P3 | recruiting | A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma |
| NCT05243797 | MajesTEC-4 | P3 | recruiting | Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation |
| NCT07258511 | TRIlogy-4 | P3 | recruiting | A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma |
| NCT06577025 | aMMbition | P2 | active not recruiting | A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma |
| NCT05572229 | IFM2021-01 | P2 | recruiting | Study of Teclistamab in Combination in Elderly Patients With Multiple Myeloma |
| NCT06353022 | IFm2022-01 | P2 | active not recruiting | Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma |
| NCT06100237 | REVIVE | P2 | recruiting | Teclistamab in Combination With Daratumumab for High-Risk Smoldering Myeloma: A Clinical and Correlative Phase 2 Immuno-Oncology Study (the REVIVE Study) |
| + 15 more, see All trials below. | ||||
Recurrent Multiple Myeloma (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06948084 | — | P2 | not yet recruiting | Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse |
| NCT06465316 | TECVAYLI | P1 | recruiting | Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma |
| NCT07463807 | — | P1/P2 | not yet recruiting | Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment |
| NCT06588660 | — | P1 | terminated | ST-067 and Teclistamab for the Treatment of Relapsed or Refractory Multiple Myeloma |
AL Amyloidosis (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06935162 | — | P2 | recruiting | Teclistamab in Previously Treated AL Amyloidosis |
| NCT06649695 | AL | P2 | recruiting | A Phase II Trial of Teclistamab in Participants With Previously Treated Immunoglobulin Light-chain (AL) Amyloidosis |
| NCT07079423 | — | P2 | recruiting | Teclistamab in Newly Diagnosed Mayo Stage IIIB AL Amyloidosis |
| NCT06699394 | — | N/A | recruiting | Prospective Study of Teclistamab in the Treatment of Systemic AL Amyloidosis |
Relapsed or Refractory Multiple Myeloma (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05572515 | MajesTEC-9 | P3 | active not recruiting | A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma |
| NCT06425991 | MajesTEC-10 | P1 | active not recruiting | A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma |
| NCT05463939 | — | N/A | approved for marketing | Teclistamab Expanded Access Treatment Protocol for Relapsed or Refractory Multiple Myeloma Patients |
Multiple Myeloma (MM) (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07107529 | — | P2 | recruiting | Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab. |
| NCT07029776 | — | P2 | not yet recruiting | MMulti-Immune HR; Multi-Target Immunotherapy for High-Risk Multiple Myeloma |
Hematological Malignancies (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04557098 | MajesTEC-1 | P2 | active not recruiting | A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma |
| NCT03145181 | MajesTEC-1 | P1 | active not recruiting | Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma |
Waldenstrom Macroglobulinaemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07474961 | BLOOD-dose | P4 | not yet recruiting | BLOOD-dose: A Platform Trial Evaluating Dose Optimization in Hematological Diseases. |
Recurrent Plasmablastic Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07332507 | — | P1 | not yet recruiting | Testing the Effect of Teclistamab on Recurrent Plasmablastic Lymphoma |
Amyloid Light-chain Amyloidosis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07110844 | — | P2 | recruiting | Teclistamab-Daratumumab in AL Amyloidosis |
Multiple Myleoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06880601 | TALIM | P2 | not yet recruiting | Teclistamab Plus Autologous Lymphocyte Infusion (ALI) for the Treatment of R/R Multiple Myeloma |
Multiple Myeloma, Newly Diagnosed (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06758375 | — | P2 | recruiting | Low Dose Teclistamab in Newly Diagnosed Multiple Myeloma Patients |
Myeloma Multiple (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06855121 | NIMMS | N/A | recruiting | The Norwegian Immunotherapy in Multiple Myeloma Study |
Relapse Multiple Myeloma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06171685 | MMRC-099 | P2 | active not recruiting | MMRC Horizon One: RRMM (MMRC-099) |
High-Risk de Novo Multiple Myeloma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05849610 | GEM-TECTAL | P2 | active not recruiting | Teclistamab-Daratumumab and Talquestamab-Daratumumab in Newly Diagnosed High-risk Multiple Myeloma |
High-risk Smoldering Multiple Myeloma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05469893 | — | P2 | recruiting | Immuno-PRISM (PRecision Intervention Smoldering Myeloma) |
Relapsed/ Refractory Multiple Myeloma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05338775 | TRIMM-3 | P1 | active not recruiting | A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma |
Hematologic Malignancies (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04696809 | — | P1/P2 | completed | A Study of Teclistamab in Japanese Participants With Relapsed or Refractory Multiple Myeloma |
Haematological Malignancy (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04068597 | — | P1/P2 | recruiting | Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies |
Teclistamab pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| BLOOD-dose | NCT07474961 | P4 | not yet recruiting | Waldenstrom Macroglobulinaemia | 400 | — |
| MajesTEC-7 | NCT05552222 | P3 | recruiting | Multiple Myeloma | 1,590 | — |
| TRIlogy-5 | NCT07518186 | P3 | recruiting | Multiple Myeloma | 700 | — |
| MajesTEC-4 | NCT05243797 | P3 | recruiting | Multiple Myeloma | 1,594 | — |
| TRIlogy-4 | NCT07258511 | P3 | recruiting | Multiple Myeloma | 400 | — |
| MajesTEC-9 | NCT05572515 | P3 | active not recruiting | Relapsed or Refractory Multiple Myeloma | 614 | — |
| MonumenTAL-6 | NCT06208150 | P3 | recruiting | Multiple Myeloma | 795 | — |
| MajesTEC-3 | NCT05083169 | P3 | active not recruiting | Multiple Myeloma | 587 | — |
| aMMbition | NCT06577025 | P2 | active not recruiting | Multiple Myeloma | 43 | — |
| IFM2021-01 | NCT05572229 | P2 | recruiting | Multiple Myeloma | 74 | — |
| MMRC-099 | NCT06171685 | P2 | active not recruiting | Relapse Multiple Myeloma | 300 | — |
| IFm2022-01 | NCT06353022 | P2 | active not recruiting | Multiple Myeloma | 103 | — |
| REVIVE | NCT06100237 | P2 | recruiting | Multiple Myeloma | 50 | — |
| TALIM | NCT06880601 | P2 | not yet recruiting | Multiple Myleoma | 52 | — |
| HD10/DSMMXX | NCT05695508 | P2 | recruiting | Multiple Myeloma | 160 | — |
| ROTATE | NCT06993675 | P2 | recruiting | Multiple Myeloma | 50 | — |
| GEM-TECTAL | NCT05849610 | P2 | active not recruiting | High-Risk de Novo Multiple Myeloma | 30 | — |
| TALTEC | NCT06505369 | P2 | recruiting | Multiple Myeloma | 50 | — |
| AL | NCT06649695 | P2 | recruiting | AL Amyloidosis | 30 | — |
| MajesTEC-1 | NCT04557098 | P2 | active not recruiting | Hematological Malignancies | 194 | — |
Terminated and withdrawn Teclistamab trials (2)
Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.
- NCT06352866withdrawnSiltuximab for Cytokine Release Syndrome Prophylaxis Prior to tx w/ Teclistamab in RRMM
- NCT06588660terminatedST-067 and Teclistamab for the Treatment of Relapsed or Refractory Multiple Myeloma
All Teclistamab trials (50)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT06855121 | NIMMS | The Norwegian Immunotherapy in Multiple Myeloma Study | — | recruiting | 400 | St. Olavs Hospital | Jan 2025 |
| NCT07474961 | BLOOD-dose | BLOOD-dose: A Platform Trial Evaluating Dose Optimization in Hematological Diseases. | P4 | not yet recruiting | 400 | Anne Louise Tølbøll Sørensen | Mar 2027 |
| NCT07107529 | Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab. | P2 | recruiting | 150 | European Myeloma Network B.V. | Dec 2025 | |
| NCT07110844 | Teclistamab-Daratumumab in AL Amyloidosis | P2 | recruiting | 25 | Suzanne Lentzsch, MD | Nov 2025 | |
| NCT05552222 | MajesTEC-7 | A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma | P3 | recruiting | 1,590 | Janssen Research & Development, LLC | Oct 2022 |
| NCT07518186 | TRIlogy-5 | A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma | P3 | recruiting | 700 | Janssen Research & Development, LLC | May 2026 |
| NCT05243797 | MajesTEC-4 | Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation | P3 | recruiting | 1,594 | European Myeloma Network B.V. | Sep 2022 |
| NCT07029776 | MMulti-Immune HR; Multi-Target Immunotherapy for High-Risk Multiple Myeloma | P2 | not yet recruiting | 50 | University of Arkansas | Jul 2026 | |
| NCT07258511 | TRIlogy-4 | A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma | P3 | recruiting | 400 | Janssen Research & Development, LLC | Feb 2026 |
| NCT05572515 | MajesTEC-9 | A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma | P3 | active not recruiting | 614 | Janssen Research & Development, LLC | Mar 2023 |
| NCT06577025 | aMMbition | A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma | P2 | active not recruiting | 43 | Janssen Research & Development, LLC | Aug 2024 |
| NCT05572229 | IFM2021-01 | Study of Teclistamab in Combination in Elderly Patients With Multiple Myeloma | P2 | recruiting | 74 | University Hospital, Lille | Dec 2023 |
| NCT06171685 | MMRC-099 | MMRC Horizon One: RRMM (MMRC-099) | P2 | active not recruiting | 300 | Multiple Myeloma Research Consortium | Nov 2024 |
| NCT05469893 | Immuno-PRISM (PRecision Intervention Smoldering Myeloma) | P2 | recruiting | 52 | Irene Ghobrial, MD | Aug 2022 | |
| NCT06353022 | IFm2022-01 | Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma | P2 | active not recruiting | 103 | Nantes University Hospital | Jun 2024 |
| NCT06100237 | REVIVE | Teclistamab in Combination With Daratumumab for High-Risk Smoldering Myeloma: A Clinical and Correlative Phase 2 Immuno-Oncology Study (the REVIVE Study) | P2 | recruiting | 50 | Carl Ola Landgren, MD, PhD | Dec 2023 |
| NCT06880601 | TALIM | Teclistamab Plus Autologous Lymphocyte Infusion (ALI) for the Treatment of R/R Multiple Myeloma | P2 | not yet recruiting | 52 | Gruppo Italiano Malattie EMatologiche dell'Adulto | Nov 2025 |
| NCT05695508 | HD10/DSMMXX | GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5 | P2 | recruiting | 160 | University of Heidelberg Medical Center | Dec 2022 |
| NCT06993675 | ROTATE | Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE) | P2 | recruiting | 50 | Noffar Bar | Aug 2025 |
| NCT05849610 | GEM-TECTAL | Teclistamab-Daratumumab and Talquestamab-Daratumumab in Newly Diagnosed High-risk Multiple Myeloma | P2 | active not recruiting | 30 | PETHEMA Foundation | Sep 2023 |
| NCT06935162 | Teclistamab in Previously Treated AL Amyloidosis | P2 | recruiting | 30 | Peking Union Medical College Hospital | May 2025 | |
| NCT06208150 | MonumenTAL-6 | A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide | P3 | recruiting | 795 | Janssen Research & Development, LLC | Jan 2024 |
| NCT05083169 | MajesTEC-3 | A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma | P3 | active not recruiting | 587 | Janssen Research & Development, LLC | Oct 2021 |
| NCT06505369 | TALTEC | Bispecific T-cell Redirectors as Part of First Line Treatment in Transplant Eligible Multiple Myeloma Patients | P2 | recruiting | 50 | North Estonia Medical Centre | Jun 2024 |
| NCT06649695 | AL | A Phase II Trial of Teclistamab in Participants With Previously Treated Immunoglobulin Light-chain (AL) Amyloidosis | P2 | recruiting | 30 | European Myeloma Network B.V. | Jul 2025 |
| NCT07105059 | A Study of Teclistamab and Mezigdomide in People With Multiple Myeloma | P1 | recruiting | 18 | Memorial Sloan Kettering Cancer Center | Aug 2025 | |
| NCT06948084 | Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse | P2 | not yet recruiting | 80 | National Cancer Institute (NCI) | Aug 2026 | |
| NCT07079423 | Teclistamab in Newly Diagnosed Mayo Stage IIIB AL Amyloidosis | P2 | recruiting | 35 | Peking Union Medical College Hospital | Jun 2025 | |
| NCT05972135 | Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma | P2 | recruiting | 100 | SCRI Development Innovations, LLC | Oct 2023 | |
| NCT04722146 | MajesTEC-2 | A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma | P1 | active not recruiting | 140 | Janssen Research & Development, LLC | Mar 2021 |
| NCT06477783 | TECTONIC | Study on the Clinical Efficacy of Teclistamab | — | recruiting | 100 | Universitaire Ziekenhuizen KU Leuven | Dec 2024 |
| NCT07030517 | A Study to Assess Safety of Teclistamab in Indian Participants With Relapsed and Refractory Multiple Myeloma | P4 | recruiting | 75 | Johnson & Johnson Private Limited | May 2025 | |
| NCT04557098 | MajesTEC-1 | A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma | P2 | active not recruiting | 194 | Janssen Research & Development, LLC | Sep 2020 |
| NCT03145181 | MajesTEC-1 | Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma | P1 | active not recruiting | 302 | Janssen Research & Development, LLC | May 2017 |
| NCT05338775 | TRIMM-3 | A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma | P1 | active not recruiting | 74 | Janssen Research & Development, LLC | May 2022 |
| NCT04108195 | A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma | P1 | active not recruiting | 290 | Janssen Research & Development, LLC | Feb 2020 | |
| NCT04068597 | Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies | P1/P2 | recruiting | 250 | CellCentric Ltd. | Aug 2019 | |
| NCT06425991 | MajesTEC-10 | A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma | P1 | active not recruiting | 108 | Janssen Research & Development, LLC | Jun 2024 |
| NCT07332507 | Testing the Effect of Teclistamab on Recurrent Plasmablastic Lymphoma | P1 | not yet recruiting | 30 | National Cancer Institute (NCI) | May 2026 | |
| NCT06699394 | Prospective Study of Teclistamab in the Treatment of Systemic AL Amyloidosis | N/A | recruiting | 20 | Peking University People's Hospital | Mar 2025 | |
| NCT06465316 | TECVAYLI | Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma | P1 | recruiting | 26 | National Cancer Institute (NCI) | Dec 2024 |
| NCT06758375 | Low Dose Teclistamab in Newly Diagnosed Multiple Myeloma Patients | P2 | recruiting | 10 | Hospital Universitario Dr. Jose E. Gonzalez | Mar 2025 | |
| NCT06251076 | Plan Development for Giving Teclistamab in the Outpatient Setting | P4 | recruiting | 15 | University Health Network, Toronto | Nov 2024 | |
| NCT04586426 | RedirecTT-1 | A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma | P1/P2 | active not recruiting | 228 | Janssen Research & Development, LLC | Dec 2020 |
| NCT07463807 | Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment | P1/P2 | not yet recruiting | 162 | National Cancer Institute (NCI) | Jun 2026 | |
| NCT04696809 | A Study of Teclistamab in Japanese Participants With Relapsed or Refractory Multiple Myeloma | P1/P2 | completed | 40 | Janssen Pharmaceutical K.K. | Feb 2021 | |
| NCT06352866 | Siltuximab for Cytokine Release Syndrome Prophylaxis Prior to tx w/ Teclistamab in RRMM | P2 | withdrawn | 0 | Jack Khouri, MD | Jan 2025 | |
| NCT06588660 | ST-067 and Teclistamab for the Treatment of Relapsed or Refractory Multiple Myeloma | P1 | terminated | 1 | University of Washington | Dec 2024 | |
| NCT05463939 | Teclistamab Expanded Access Treatment Protocol for Relapsed or Refractory Multiple Myeloma Patients | — | approved for marketing | 0 | Janssen Research & Development, LLC | — | |
| NCT05161598 | JNJ-64007957 | Pre-approval Access Single Patient Request for Teclistamab (JNJ-64007957) | — | no longer available | 0 | Janssen Research & Development, LLC | — |
Teclistamab clinical trials: frequently asked questions
- How many Teclistamab clinical trials are there?
- 50 Teclistamab clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 26 are actively recruiting participants. 1 is marked completed.
- Are Teclistamab clinical trials recruiting in 2026?
- Yes — 26 Teclistamab trials are actively recruiting in 2026, with 183 U.S. sites across 38 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is Teclistamab being studied for?
- Teclistamab is being studied for Multiple Myeloma, Refractory Multiple Myeloma, AL Amyloidosis, Recurrent Multiple Myeloma, Relapsed or Refractory Multiple Myeloma and 28 more. The trials are grouped by indication on this page.
- What phase is Teclistamab in?
- Teclistamab clinical trials span 3 Phase 4, 7 Phase 3, 22 Phase 2, 9 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Teclistamab clinical trials?
- The lead sponsor across the most Teclistamab trials is Janssen Research & Development, LLC, with 28 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Teclistamabas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: